European IPOs Hold Their Own

01 Apr 2007

• By Melanie Senior

The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists. The wisdom's changed (or some of it, anyway).

The conventional wisdom is that European biopharma IPOs lag those in the US both in number and average size, held back by fragmented markets, stingy risk-averse investors, and a lack of specialists.

The wisdom’s changed (or some of it, anyway). Granted, IPOs worldwide in biopharma are still playing second fiddle to M&A,...